CMT affects 1/2500 people and there are no proven treatments that modify the disease. Clinical and basic research in inherited peripheral neuropathies is expanding rapidly on many fronts. Next generation sequencing enables the identification of novel genetic causes such that > 90 genes causing CMT neuropathy have now been identified, many by sites within the INC. Rational therapeutic approaches for the most common subtypes of CMT are being actively pursued or have even already developed. The INC needs to rapidly respond to new opportunities and needs that result from novel discoveries in fields such as genetic diagnosis, gene editing, cell biology, or outcome measures in CMT. To this end we propose a Pilot/Feasibility Core to support single- or multi-site projects that will advance the diagnosis, clinical trial readiness, management, and/or treatment of CMT subtypes. Approved projects will typically be approved for a single year, with a budget of $25,000 to $50,000. Funds will be available to support two Pilot/Feasibility projects per year. Junior INC investigators and senior investigators wishing to expand their research in new directions will be encouraged to apply. Evaluating Pilot/Feasibility applications and monitoring the projects will be the responsibility of the Pilot/Feasibility Core, which will be directed by Dr. Mario Saporta (the site-PI of the clinical University of Miami site and Dr. Alex Rossor (from our UCL site). They were the first two scholar/trainees of the INC 10 years ago, and are now recognized as independent investigators in our field. Core membership includes expertise in COAs, genetic diagnosis, and therapeutic development. Members include the INC leadership - Drs. Shy, Scherer, Herrmann, Reilly, Zchner, and Burns, as well as Drs. Finkel (an expert in neuromuscular trials) and Svaren (a member of our External Advisory Committee, and an expert in biomarker development) and representatives from two PAGS, Amy Gray (CMTA) and Dr. Amanda Haidet-Phillips (MDA).
| Hu, Bo; McCollum, Megan; Ravi, Vignesh et al. (2018) Myelin abnormality in Charcot-Marie-Tooth type 4J recapitulates features of acquired demyelination. Ann Neurol 83:756-770 |
| Dankwa, Lois; Richardson, Jessica; Motley, William W et al. (2018) A mutation in the heptad repeat 2 domain of MFN2 in a large CMT2A family. J Peripher Nerv Syst 23:36-39 |
| Bai, Yunhong; Wu, Xingyao; Brennan, Kathryn M et al. (2018) Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B. Ann Clin Transl Neurol 5:445-455 |
| Rebelo, Adriana P; Saade, Dimah; Pereira, Claudia V et al. (2018) SCO2 mutations cause early-onset axonal Charcot-Marie-Tooth disease associated with cellular copper deficiency. Brain 141:662-672 |
| Abbott, Jamie A; Meyer-Schuman, Rebecca; Lupo, Vincenzo et al. (2018) Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. Hum Mutat 39:415-432 |
| Abrams, Alexander J; Fontanesi, Flavia; Tan, Natalie B L et al. (2018) Insights into the genotype-phenotype correlation and molecular function of SLC25A46. Hum Mutat 39:1995-2007 |
| Sandelius, Åsa; Zetterberg, Henrik; Blennow, Kaj et al. (2018) Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology 90:e518-e524 |
| Lassuthova, Petra; Rebelo, Adriana P; Ravenscroft, Gianina et al. (2018) Mutations in ATP1A1 Cause Dominant Charcot-Marie-Tooth Type 2. Am J Hum Genet 102:505-514 |
| Panosyan, Francis B; Kirk, Callyn A; Marking, Devon et al. (2018) Carpal tunnel syndrome in inherited neuropathies: A retrospective survey. Muscle Nerve 57:388-394 |
| Synofzik, Matthis; Helbig, Katherine L; Harmuth, Florian et al. (2018) De novo ITPR1 variants are a recurrent cause of early-onset ataxia, acting via loss of channel function. Eur J Hum Genet 26:1623-1634 |
Showing the most recent 10 out of 189 publications
